GHENT, Belgium, 18 June 2007 - Ablynx, the pioneer in the discovery and development of Nanobodies® has announced that its collaboration agreement with Procter & Gamble Pharmaceuticals Inc. (P&GP), a division of The Procter & Gamble Company, has reached a second milestone. Ablynx has discovered novel Nanobodies® against a second target for possible new treatments in the musculoskeletal area. The first milestone under this collaboration was achieved in December 2006 and was also a target for musculoskeletal diseases.
